The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Ictastan 200 mg/245 mg film-coated tablets

200 mg/245 milligram(s) Film-coated tablet

Accord Healthcare Ireland Ltd.PA2315/153/001

Main Information

Trade NameIctastan 200 mg/245 mg film-coated tablets
Active SubstancesEmtricitabine
Tenofovir disoproxil
Strength200 mg/245 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderAccord Healthcare Ireland Ltd.
Licence NumberPA2315/153/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR03 tenofovir disoproxil and emtricitabine

Status

Authorised/WithdrawnAuthorised
Licence Issued06/05/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available

Educational Materials - HCP

Generics Information

Interchangeable List CodeIC0107-165-003
Interchangeable List DocumentPDF of Interchangeable List
« Back